Bulk Pharmaceutical API Sources for hydrocortisone butyrate

Bulk Pharmaceutical API Sources for hydrocortisone butyrate

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		H5270_SIGMA
Molport		MolPort-003-941-574
Hangzhou APIChem Technology		AC-492
TimTec		ST075194
Amadis Chemical		A807026
AKos Consulting & Solutions		AKOS015895443

Hydrocortisone Butyrate API Sourcing Landscape

Last updated: February 19, 2026

Hydrocortisone butyrate, a mid-potency topical corticosteroid, is a critical component in dermatological formulations for treating inflammatory skin conditions. Sourcing bulk Active Pharmaceutical Ingredient (API) for this compound involves navigating a global supply chain with established manufacturers in Asia, primarily China and India, alongside specialized producers in Europe and North America. Key considerations for procurement include API quality, regulatory compliance, manufacturing capacity, and cost-effectiveness.

What are the Primary Global Sources for Hydrocortisone Butyrate API?

The global supply of hydrocortisone butyrate API is concentrated in regions with established pharmaceutical manufacturing infrastructure and expertise in steroid synthesis.

• China: This region is a dominant supplier, with numerous API manufacturers capable of producing hydrocortisone butyrate to international quality standards. Companies benefit from economies of scale and a well-developed chemical synthesis sector.

  • Key Manufacturers: Zhejiang NHU Co., Ltd., Xiamen Koryo Chemical Industry Co., Ltd.
  • Estimated Production Capacity: Significant, often catering to multiple global markets.
  • Regulatory Standing: Many manufacturers hold certifications such as GMP (Good Manufacturing Practice), ISO, and HACCP. Drug Master Files (DMFs) are commonly filed with regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• India: Another major hub for API production, Indian manufacturers offer competitive pricing and adhere to stringent quality controls. The country has a robust pharmaceutical industry with extensive experience in complex organic synthesis.

  • Key Manufacturers: Divi's Laboratories, Aarti Industries, Solara Active Pharma Sciences.
  • Estimated Production Capacity: High, with many facilities operating at multi-ton scales annually.
  • Regulatory Standing: Indian facilities are frequently inspected and approved by global regulatory bodies, including the FDA, EMA, and WHO. DMFs are standard practice for export markets.

• Europe: European manufacturers often focus on specialized, high-purity grades and may offer localized supply chains or specific regulatory advantages for European markets.

  • Key Manufacturers: Siegfried AG, BASF SE (though BASF's portfolio may vary, it is a significant player in fine chemicals).
  • Estimated Production Capacity: Moderate to high, with some facilities specializing in niche steroid derivatives.
  • Regulatory Standing: Manufacturers typically comply with EMA GMP standards, and many hold Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs).

• North America: While less dominant in sheer volume compared to Asia, North American manufacturers provide a domestic supply option and are known for rigorous quality control and regulatory adherence.

  • Key Manufacturers: Companies within the U.S. and Canada specializing in steroid synthesis or custom API manufacturing. Specific large-scale hydrocortisone butyrate producers are less publicly disclosed than their Asian counterparts.
  • Estimated Production Capacity: Variable, often serving domestic demand or niche markets.
  • Regulatory Standing: Compliance with FDA GMP is paramount.

What are the Regulatory Requirements for Hydrocortisone Butyrate API Procurement?

Procuring hydrocortisone butyrate API necessitates strict adherence to international pharmaceutical regulatory standards.

• Good Manufacturing Practice (GMP): Manufacturers must demonstrate compliance with GMP guidelines as set forth by regulatory bodies such as the FDA (21 CFR Parts 210 & 211), EMA (EudraLex Volume 4), and WHO. This ensures consistent quality, purity, and safety of the API.
• Drug Master Files (DMFs): Suppliers typically file DMFs with regulatory authorities. A DMF provides confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows regulatory agencies to review the API information without disclosing proprietary details to the drug product manufacturer.
  • U.S. FDA DMF Type II: This is the relevant type for API production.
  • European CEP: A Certificate of Suitability to the monographs of the European Pharmacopoeia can expedite the regulatory process for European submissions.
• Pharmacopoeial Compliance: The API must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). Key parameters include:
  • Assay (typically 97.0% to 102.0%)
  • Related substances (limits for specific impurities)
  • Residual solvents
  • Water content
  • Identification tests
• Impurity Profiling: Manufacturers must identify, quantify, and control process-related impurities and degradation products. This is critical for patient safety and regulatory approval. ICH Q3A (R2) and Q3C (R6) guidelines provide frameworks for impurity control.
• Stability Studies: Comprehensive stability data, conducted according to ICH guidelines (e.g., Q1A(R2)), is required to establish the retest period or shelf life of the API under defined storage conditions.
• Audits and Inspections: Pharmaceutical companies must conduct audits of their API suppliers to verify GMP compliance and assess manufacturing capabilities. Regulatory agencies also conduct inspections of API manufacturing sites.

How Does API Quality and Purity Vary Among Suppliers?

Quality and purity are paramount for hydrocortisone butyrate API. Variations can stem from manufacturing processes, raw material sourcing, and analytical testing protocols.

• Impurity Levels: The types and levels of impurities can differ significantly. Some suppliers may have more robust purification processes, leading to lower levels of specific related substances or residual solvents.
  • Example: A supplier might consistently demonstrate <0.1% for a specific critical impurity, while another may have a limit of <0.5%.
• Polymorphism: Hydrocortisone butyrate can exist in different polymorphic forms, which can affect solubility, dissolution rate, and bioavailability of the final drug product. Reputable suppliers will characterize and control the polymorphic form of their API.
• Particle Size Distribution (PSD): For topical formulations, PSD is crucial for consistent drug release and texture. Manufacturers may offer different grades with tailored PSDs.
  • Example: Micronized grades may be available for enhanced dissolution.
• Assay Consistency: While pharmacopoeial limits are broad (e.g., 97.0% to 102.0%), consistent high-assay API can reduce batch-to-batch variability in the finished product.
• Residual Solvents: Different synthetic routes may employ varying solvents. Suppliers adhering to ICH Q3C guidelines will ensure that residual solvent levels are within acceptable limits.

What are the Cost Factors and Market Dynamics for Hydrocortisone Butyrate API?

The cost of hydrocortisone butyrate API is influenced by a combination of manufacturing, regulatory, and market factors.

• Manufacturing Costs:
  • Raw Material Sourcing: The cost of precursor steroids and reagents is a primary driver.
  • Synthesis Complexity: Multi-step steroid synthesis is capital-intensive and requires specialized expertise.
  • Energy and Labor: Costs vary geographically.
  • Yield and Efficiency: Higher yields translate to lower per-kilogram costs.
• Regulatory Compliance: The investment in maintaining GMP facilities, conducting extensive testing, and filing DMFs adds to the overall cost.
• Economies of Scale: Larger production volumes generally lead to lower per-unit costs. Manufacturers with high capacities can offer more competitive pricing.
• Geopolitical Factors and Trade Policies: Tariffs, trade agreements, and geopolitical stability can impact raw material availability and final API pricing.
• Supply and Demand: Fluctuations in demand from the pharmaceutical industry, driven by generic product launches or increased prevalence of dermatological conditions, can affect pricing.
• Supplier Competition: A competitive market with multiple qualified suppliers can lead to price pressures.
  • Typical Price Range: Bulk hydrocortisone butyrate API can range from approximately $50 to $200 per kilogram, depending on supplier, quality, volume, and regulatory status. (Note: This is an indicative range and actual prices may vary.)

What are the Key Considerations for Establishing a Reliable Supply Chain?

Securing a consistent and high-quality supply of hydrocortisone butyrate API requires a strategic approach to supplier selection and relationship management.

• Supplier Qualification:
  • Audits: Conduct thorough on-site GMP audits.
  • Quality Agreements: Establish detailed quality agreements outlining responsibilities, specifications, change control, and deviation management.
  • Regulatory Track Record: Review the supplier's history of regulatory inspections and DMF filings.
• Supply Chain Risk Assessment:
  • Geographic Diversification: Consider dual-sourcing from different geographic regions to mitigate risks associated with regional disruptions (e.g., natural disasters, political instability).
  • Financial Stability: Assess the financial health of potential suppliers.
• Lead Times and Inventory Management:
  • Production Capacity: Understand the supplier's production capacity and typical lead times for large orders.
  • Inventory Buffers: Maintain appropriate inventory levels to buffer against unforeseen supply interruptions.
• Intellectual Property (IP) Protection: For novel formulations or processes that may involve specific API characteristics, ensure that IP considerations are addressed, particularly if custom synthesis or development is involved.

Key Takeaways

The global sourcing of hydrocortisone butyrate API is dominated by manufacturers in China and India, with significant contributions from Europe and North America. Procurement requires strict adherence to GMP, pharmacopoeial standards, and the successful filing of regulatory documentation like DMFs. Quality and purity vary based on manufacturing processes and impurity control, impacting API suitability for pharmaceutical formulations. Cost is driven by manufacturing expenses, regulatory overhead, scale of production, and market dynamics. Establishing a reliable supply chain involves rigorous supplier qualification, risk assessment, and strategic inventory management.

Frequently Asked Questions

What is the typical shelf life of hydrocortisone butyrate API?

API shelf life is determined by stability studies and typically ranges from 2 to 5 years under recommended storage conditions. Suppliers will provide a retest date or expiry date based on ICH guideline compliance.

Can hydrocortisone butyrate API be sourced with specific particle size distributions?

Yes, many manufacturers offer hydrocortisone butyrate API with controlled particle size distributions, often through micronization processes, to meet the specific requirements of topical formulations.

What is the impact of a supplier's regulatory history on API procurement?

A strong regulatory history, evidenced by successful FDA, EMA, or other major agency inspections and accepted DMFs, significantly de-risks the procurement process and facilitates faster regulatory approval of the finished drug product.

How does the cost of hydrocortisone butyrate API compare between Asian and European/North American suppliers?

Generally, API sourced from China and India tends to be more cost-competitive due to economies of scale and lower manufacturing overheads. European and North American suppliers may offer premiums for localized supply, specialized quality, or specific regulatory advantages.

What are the common impurities found in hydrocortisone butyrate API and how are they controlled?

Common impurities can include process-related impurities from synthesis intermediates or by-products, and degradation products. Control strategies involve rigorous purification steps, validated analytical methods, and adherence to ICH guidelines for impurity identification and limits.

Citations

[1] U.S. Food and Drug Administration. (n.d.). 21 CFR Part 210 - Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General. Retrieved from [FDA Website]

[2] European Medicines Agency. (n.d.). EudraLex Volume 4: Good manufacturing practice (GMP) guidelines. Retrieved from [EMA Website]

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Tripartite Guideline: Impurities in New Drug Substances Q3A(R2).

[4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2017). ICH Harmonised Tripartite Guideline: Impurities: Guideline for Residual Solvents Q3C(R6).

[5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2003). ICH Harmonised Tripartite Guideline: Stability Testing of New Drug Substances and Products Q1A(R2).